A Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors

Summary

This clinical trial is a Phase 1-2, open-label, sequential-group, dose-escalation and cohort-expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of daily oral administration of eFT508.

Timeline

Start

2015-12-03

Primary completion

2019-01-11

Completion

2019-03-22

Outcome

Outcome not reported

Stopped: “The study was terminated after determination of the RP2D, prior to opening expansion cohorts)”

Drugs

Indications